PAX-5: A valuable immunohistochemical marker in the differential diagnosis of lymphoid neoplasms

Clinical Medicine and Research

Volumn 8, Issue 2, 2010, Pages 84-88

  Desouki, Mohamed M ^a   Post, Ginell R ^c   Cherry, Daniel ^b   Lazarchick, John ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MUSC Medical Center   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Anaplastic large cell lymphoma; Diffuse large B cell lymphoma; Hodgkin lymphoma; PAX 5; Undifferentiated tumors

Indexed keywords

MONOCLONAL ANTIBODY; TRANSCRIPTION FACTOR PAX5; PAX5 PROTEIN, HUMAN; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; BONE MARROW BIOPSY; CARCINOID; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LARGE CELL LYMPHOMA; LYMPH NODE BIOPSY; LYMPHOMA; MAJOR CLINICAL STUDY; MELANOMA; PROTEIN ANALYSIS; RETROSPECTIVE STUDY; T CELL LEUKEMIA; TISSUE MICROARRAY; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, LARGE-CELL, ANAPLASTIC;

B-CELL-SPECIFIC ACTIVATOR PROTEIN; DIAGNOSIS, DIFFERENTIAL; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, LARGE-CELL, ANAPLASTIC; TUMOR MARKERS, BIOLOGICAL;

EID: 77957220259     PISSN: 15394182     EISSN: None     Source Type: Journal    
DOI: 10.3121/cmr.2010.891     Document Type: Article

References (27)

1. Tzankov A, Bourgau C, Kaiser A, Zimpfer A, Maurer R, Pileri SA, Went P, Dirnhofer S. Rare expression of T-cell markers in classical Hodgkin's lymphoma. Mod Pathol 2005;18:1542-1549.
2. Foran JM, Norton AJ, Micallef IN, Taussig DC, Amess JA, Rohatiner AZ, Lister TA. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis. Br J Haematol 2001;114:881-883.
3. Chu PG, Chen YY, Molina A, Arber DA, Weiss LM. Recurrent B-cell neoplasms after Rituximab therapy: an immunophenotypic and genotypic study. Leuk Lymphoma 2002;43:2335-2341.
4. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 1999;5:611-615.
5. Palmisano WA, Crume KP, Grimes MJ, Winters SA, Toyota M, Esteller M, Joste N, Baylin SB, Belinsky SA. Aberrant promoter methylation of the transcription factor genes PAX-5 alpha and beta in human cancers. Cancer Res 2003;63:4620-4625.
6. Walther C, Guenet JL, Simon D, Deutsch U, Jostes B, Goulding MD, Plachov D, Balling R, Gruss P. Pax: a murine multigene family of paired box-containing genes. Genomics 1991;11:424-434.
7. Horcher M, Souabni A, Busslinger M. PAX-5/BSAP maintains the identity of B cells in late B lymphopoiesis. Immunity 2001;14:779-790.
8. Adams B, Dorfler P, Aguzzi A, Kozmik Z, Urbánek P, Maurer-Fogy I, Busslinger M. Pax-5 encodes the transcription factor BSAP and is expressed in B lymphocytes, the developing CNS, and adult testis. Genes Dev 1992;6:1589-1607.
9. Krenacs L, Himmelmann AW, Quintanilla-Martinez L, Fest T, Riva A, Wellmann A, Bagdi E, Kehrl JH, Jaffe ES, Raffeld M. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas. Blood 1998;92:1308-1316.
10. Mhawech-Fauceglia P, Saxena R, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, Penetrante R. Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis. J Clin Pathol 2007;60:709-714.
11. Jensen KC, Higgins JP, Montgomery K, Kaygusuz G, van de Rijn M, Natkunam Y. The utility of PAX5 immunohistochemistry in the diagnosis of undifferentiated malignant neoplasms. Mod Pathol 2007;20:871-877.
12. Torlakovic E, Slipicevic A, Robinson C, DeCoteau JF, Alfsen GC, Vyberg M, Chibbar R, Flørenes VA. Pax-5 expression in nonhematopoietic tissues. Am J Clin Pathol 2006;126:798-804.
13. Baumann Kubetzko FB, Di Paolo C, Maag C, Meier R, Schäfer BW, Betts DR, Stahel RA, Himmelmann A. The PAX-5 oncogene is expressed in N-type neuroblastoma cells and increases tumorigenicity of a S-type cell line. Carcinogenesis 2004;25:1839-1846.
14. Kanteti R, Nallasura V, Loganathan S, Tretiakova M, Kroll T, Krishnaswamy S, Faoro L, Cagle P, Husain AN, Vokes EE, Lang D, Salgia R. PAX-5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab Invest 2009;89:301-314.
15. Dong HY, Liu W, Cohen P, Mahle CE, Zhang W. B-cell specific activation protein encoded by the PAX-5 gene is commonly expressed in merkel cell carcinoma and small cell carcinomas. Am J Surg Pathol 2005;29:687-692.
16. Norhany S, Kouzu Y, Uzawa K, Hayama M, Higo M, Koike H, Kasamatu A, Tanzawa H. Overexpression of PAX-5 in oral carcinogenesis. Oncol Rep 2006;16:1003-1008.
17. Sullivan LM, Atkins KA, Legallo RD. PAX immunoreactivity identifies alveolar rhabdomyosarcoma. Am J Surg Pathol 2009;33:775-780.
18. Torlakovic E, Torlakovic G, Nguyen PL, Brunning RD, Delabie J. The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker. Am J Surg Pathol 2002;26:1343-1350.
19. Chu PG, Loera S, Huang Q, Weiss LM. Lineage determination of CD20- B-Cell neoplasms: an immunohistochemical study. Am J Clin Pathol 2006;126:534-544.
20. Browne P, Petrosyan K, Hernandez A, Chan JA. The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-Bcell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma. Am J Clin Pathol 2003;120:767-777.
21. McCune RC, Syrbu SI, Vasef MA. Expression profiling of transcription factors Pax-5, Oct-1, Oct-2, BOB.1, and PU.1 in Hodgkin's and non-Hodgkin's lymphomas: a comparative study using high throughput tissue microarrays. Mod Pathol 2006;19:1010-1018.
22. Tiacci E, Pileri S, Orleth A, Pacini R, Tabarrini A, Frenguelli F, Liso A, Diverio D, Lo-Coco F, Falini B. PAX-5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia. Cancer Res 2004;64:7399-7404.
23. Valbuena JR, Medeiros LJ, Rassidakis GZ, Hao S, Wu CD, Chen L, Lin P. Expression of B cell-specific activator protein/PAX5 in acute myeloid leukemia with t(8;21) (q22;q22). Am J Clin Pathol 2006;126:235-240.
24. Kita K, Nakase K, Miwa H, Masuya M, Nishii K, Morita N, Takakura N, Otsuji A, Shirakawa S, Ueda T. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood 1992;80:470-477.
25. Valbuena JR, Admirand JH, Gualco G, Medeiros LJ. Myeloid sarcoma involving the breast. Arch Pathol Lab Med 2005;129:32-38.
26. Tamaru J, Tokuhira M, Nittsu N, Nakamura S, Ichinohasama R, Suzuki R, Mori H, Takagi T, Suzuki T, Itami J, Itoyama S, Mikata A. Hodgkin-like anaplastic large cell lymphoma (previously designated in the REAL classification) has same immunophenotypic features to classical Hodgkin lymphoma. Leuk Lymphoma 2007;48:1127-1138.
27. Stein H, Desol G, Pileri SA, Weiss LM, Poppema S, Jaffe ES. Classic Hodgkin lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer (IARC);2008. 326-329.